

CHAPTER 1: INTRODUCTION	1
STUDY BACKGROUND	1
STUDY GOAL AND OBJECTIVES	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT	2
METHODOLOGY AND INFORMATION SOURCES.....	3
COMMERCIAL DRUGS	4
DEVELOPMENTAL DRUGS	4
<i>TABLE 1 FDA APPROVAL PROCESS FOR NEW DRUGS</i>	4
ANALYST CREDENTIALS.....	5
RELATED BCC PUBLICATIONS	5
BCC ONLINE SERVICES.....	5
DISCLAIMER	6
CHAPTER 2: SUMMARY	7
<i>SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 (\$ BILLIONS)</i>	8
SUMMARY (CONTINUED)	9
SUMMARY (CONTINUED)	10
CHAPTER 3: OVERVIEW	11
BRIEF HISTORY OF PLANT-DERIVED MEDICINES.....	11
BRIEF HISTORY OF PLANT-... (CONTINUED).....	12
<i>TABLE 2 KEY DATES IN BOTANICAL MEDICINE</i>	13
<i>TABLE 3 WELL KNOWN PLANT-DERIVED DRUGS</i>	13
OPPORTUNITY LIES BEYOND WHAT'S KNOWN.....	13
OPPORTUNITY LIES BEYOND ... (CONTINUED)	14
<i>FIGURE 1 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S. (2000–2005)* (%)</i>	15
KEY DRIVERS.....	16
KEY CHALLENGES.....	16
SIGNS OF INDUSTRY INVESTMENT	17
<i>TABLE 4 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT</i>	18
<i>TABLE 5 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS</i>	19
<i>TABLE 5 (CONTINUED)</i>	20
BOTANICAL DRUGS DEFINED	20
UNDERSTANDING THE REGULATORY PROCESS	21
UNDERSTANDING THE REGULATORY ... (CONTINUED).....	22
<i>TABLE 6 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY</i>	23
THE FIRST APPROVED BOTANICAL.....	23

A GROWING PIPELINE.....	24
<i>FIGURE 2 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)</i>	25
OVERALL PHARMA LANDSCAPE	26
OVERALL PHARMA LANDSCAPE (CONTINUED).....	27
<i>TABLE 7 TOP PHARMA COMPANIES BY REVENUE, 2007 (\$</i> <i>BILLIONS)</i>	28
MAJOR CLASSES OF PLANT DRUGS	28
Terpenes and Steroids.....	29
Terpenes	29
Steroids.....	29
Alkaloids and Glycosides.....	30
Alkaloids.....	30
Ergot Alkaloids.....	31
Morphine Alkaloids.....	31
Vinca Alkaloids	31
Glycosides.....	31
Cardiac Glycosides	32
Anthraglycosides.....	32
Phenols.....	32
E. Cava Algae.....	32
Flavonoids	32
Resveratrol	33
Coumarin.....	33
Catechins.....	33
Proanthocyanidins	33
INTELLECTUAL PROPERTY.....	34
PRODUCTION.....	35
PRODUCTION (CONTINUED)	36
MOVING PRODUCTION FORWARD.....	37
ARTEMISININ: A CASE STUDY	38
SUPPLY AND LEGAL ISSUES.....	39
<i>TABLE 8 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-</i> <i>BASED MEDICINALS</i>	40
DRUG DEVELOPMENT AND MANUFACTURE	40
Drug Development ... (Continued).....	41
<i>TABLE 9 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES</i>	42
CHAPTER 4: MARKET SEGMENTATION.....	43
GEOGRAPHIC SEGMENTATION.....	43
SALES OF PLANT-DERIVED DRUGS BY REGION.....	43
<i>TABLE 10 PLANT-DERIVED DRUG SALES FORECAST BY REGION,</i> <i>THROUGH 2013 (% TOTAL SALES)</i>	43
<i>FIGURE 3 GEOGRAPHIC SEGMENTATION FOR PLANT-DERIVED</i> <i>DRUGS, 2008 AND 2013 (%)</i>	44
THERAPEUTIC AREA SEGMENTATION.....	45

NUMBER OF PLANT-DERIVED DRUGS BY THERAPEUTIC AREA.....	45
<i>TABLE 11 FDA APPROVED BOTANICAL DRUGS FORECAST THROUGH 2013 (UNITS)</i>	45
<i>FIGURE 4 COMPOSITION OF FDA APPROVED BOTANICAL INDICATION FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%)*</i>	46
Value of Plant-Derived Drugs by Therapeutic Area	47
<i>TABLE 12 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPUETIC AREA, THROUGH 2013 (\$ MILLIONS)</i>	47
<i>FIGURE 5 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%)</i>	48
CHAPTER 5: THERAPEUTIC AREAS IN DETAIL FOR PLANT-DERIVED AND BOTANICAL DRUGS, THROUGH 2013.....	49
HORMONE THERAPY AND METABOLISM APPLICATIONS	49
<i>TABLE 13 PLANT-DERIVED HORMONE THERAPY AND METABOLISM DRUGS IN LATE STAGE DEVELOPMENT</i>	50
INFECTIOUS DISEASE APPLICATIONS	50
INFECTIOUS DISEASE ... (CONTINUED)	51
<i>TABLE 14 PLANT-DERIVED INFECTIOUS DISEASE DRUGS IN LATE STAGE DEVELOPMENT</i>	52
<i>TABLE 14 (CONTINUED)</i>	53
<i>TABLE 14 (CONTINUED)</i>	54
<i>TABLE 14 (CONTINUED)</i>	55
PAIN AND CENTRAL NERVOUS SYSTEM DISEASE APPLICATIONS	56
<i>TABLE 15 BRAIN DISORDERS THAT ARE REFRACTORY TO SMALL MOLECULE DRUGS</i>	57
<i>TABLE 16 PLANT-DERIVED PAIN AND CNS DRUGS IN LATE STAGE DEVELOPMENT</i>	57
<i>TABLE 16 (CONTINUED)</i>	58
<i>TABLE 16 (CONTINUED)</i>	59
<i>TABLE 16 (CONTINUED)</i>	60
CARDIOVASCULAR AND METABOLIC DISEASE.....	60
<i>TABLE 17 PLANT-DERIVED CARDIOVASCULAR AND METABOLIC DRUGS IN LATE STAGE DEVELOPMENT</i>	61
RESPIRATORY, INFLAMMATION, AND AUTOIMMUNE.....	62
<i>TABLE 18 PLANT-DERIVED RESPIRATORY, INFLAMMATION, AND AUTOIMMUNE DRUGS IN LATE STAGE DEVELOPMENT</i>	63
<i>TABLE 18 (CONTINUED)</i>	64
DERMATOLOGY APPLICATIONS.....	64
<i>TABLE 19 PLANT-DERIVED DERMATOLOGY/WOUND CARE DRUGS IN LATE STAGE DEVELOPMENT</i>	65

<i>TABLE 19 (CONTINUED)</i>	66
GASTROINTESTINAL APPLICATIONS.....	66
<i>TABLE 20 PLANT-DERIVED GASTROINTESTINAL DRUGS IN LATE STAGE* DEVELOPMENT</i>	66
<i>TABLE 20 (CONTINUED)</i>	67
ONCOLOGY APPLICATIONS.....	67
<i>TABLE 21 ESTIMATED U.S. CANCER CASES, 2007</i>	67
<i>TABLE 21 (CONTINUED)</i>	68
<i>TABLE 22 PLANT-DERIVED ONCOLOGY DRUGS IN LATE STAGE DEVELOPMENT</i>	69
<i>TABLE 22 (CONTINUED)</i>	70
<i>TABLE 22 (CONTINUED)</i>	71
<i>TABLE 22 (CONTINUED)</i>	72
<i>TABLE 22 (CONTINUED)</i>	73
<i>TABLE 22 (CONTINUED)</i>	74
<i>TABLE 22 (CONTINUED)</i>	75
<i>TABLE 22 (CONTINUED)</i>	76
<i>TABLE 22 (CONTINUED)</i>	77
<i>TABLE 23 BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT WITH EXPECTED FDA-APPROVED COMMERCIALIZATION, THROUGH 2013*</i>	77
<i>TABLE 23 (CONTINUED)</i>	78
CHAPTER 6: COMPANY PROFILES	79
ADVANCED LIFE SCIENCES	79
ARTECEF B.V.....	79
AMERICAN ORIENTAL BIOENGINEERING.....	80
ANALYTICON DISCOVERY GMBH.....	81
AVESTHAGEN, LTD.....	81
BAYER SCHERING	82
BIONUMERIK PHARMACEUTICALS, INC.....	83
BIONOVO, INC.....	83
BIONOVO, INC. (CONTINUED)	84
BOEHRINGER INGELHEIM	85
PHARMATON SA	85
BRISTOL MYERS SQUIBB	86
CARDAX PHARMACEUTICALS.....	87
CHONG KUN DANG PHARMACEUTICAL CORPORATION	88
CUBIST PHARMACEUTICALS, INC.	88
CURAPHARM, INC.	89
EISAI, INC.	90
EKOMED, LLC	91
ELI LILLY	91
FYTOKEM PRODUCTS, INC.	92
GALAPAGOS NV.....	93

GLAXOSMITHKLINE.....	94
GLOBAL PHARMATECH, INC.....	95
GW PHARMACEUTICALS, PLC.....	96
HETEROGENEITY, LLC.....	96
INDENA.....	97
INDENA (CONTINUED).....	98
JOHNSON & JOHNSON.....	99
LIFEPHARMS, INC.....	100
LEO PHARMA.....	101
LUPIN, LTD.....	102
LUPIN PHARMACEUTICALS, INC.....	102
MADAUS GMBH.....	102
MERA PHARMACEUTICALS, INC.....	103
MERIDIAN MEDICAL TECHNOLOGIES, INC.....	103
KING PHARMACEUTICALS, INC. (PARENT COMPANY).....	103
MERLION PHARMACEUTICALS.....	104
MEDIGENE.....	105
MEDIGENE, INC.....	105
<i>TABLE 24 MEDIGENE BOTANICAL PIPELINE.....</i>	<i>106</i>
MERCK & CO., INC.....	107
MICROBIO.....	107
NAPO PHARMACEUTICALS, INC.....	108
NEUROGESX, INC.....	108
NOVARTIS INTERNATIONAL AG.....	109
PANACOS.....	110
PHYTOMEDICAL TECHNOLOGIES.....	111
PHYTOMEDICS, INC.....	111
PHYTOMEDICS, INC. (CONTINUED).....	112
PFIZER.....	113
POLYPHENON PHARMA.....	114
POLYPHENON PHARMA (CONTINUED).....	115
PHYNOVA.....	116
<i>TABLE 25 PHYNOVA PIPELINE.....</i>	<i>117</i>
PHYTOCEUTICA, INC.....	117
PHYTOMYCO RESEARCH CORP.....	118
PHYTOPHARM, PLC.....	119
PIRAMAL ENTERPRISES, LTD.....	120
PUNISYN PHARMACEUTICALS, LTD.....	120
RANBAXY LABORATORIES, LTD.....	121
SANOFI-AVENTIS.....	121
SCHWABE PHARMACEUTICALS.....	122
SEQUOIA SCIENCES, INC.....	123
SIRTRIS.....	123
SOLVAY PHARMACEUTICALS.....	124

SUNTEN PHYTOTECH CO., LTD.....	124
<i>TABLE 26 SUNTECH PHYTOTECH PIPELINE.....</i>	<i>125</i>
TASLY PHARMACEUTICALS, INC.	125
TCM BIOTECH INTERNATIONAL CORP.....	126
VEDIC LIFESCIENCES PVT., LTD.....	127
YAUPON THERAPEUTICS.....	127
WYETH PHARMACEUTICALS	128
ZHEJIANG KANGLAITE GROUP CO, LTD.	129
ZHEJIANG KANGLAITE ... (CONTINUED).....	130
APPENDIX.....	131
<i>TABLE 27 PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONS</i>	<i>131</i>
<i>TABLE 27 (CONTINUED).....</i>	<i>132</i>
<i>TABLE 27 (CONTINUED).....</i>	<i>133</i>
<i>TABLE 27 (CONTINUED).....</i>	<i>134</i>
<i>TABLE 27 (CONTINUED).....</i>	<i>135</i>
<i>TABLE 28 USEFUL RESOURCES FOR THE BOTANICAL DRUG</i>	
<i>INDUSTRY</i>	<i>135</i>
<i>TABLE 28 (CONTINUED).....</i>	<i>136</i>